Review
Sarcoidosis 2001
D Geraint James
Royal Free
Hospital, London NW3 2QG, UK
Correspondence to: Dr James
Submitted 17 April
2000;
Accepted 22 August 2000
In every decade, sarcoidosis makes a chameleon-like change so
its profile needs to be updated. It was first recognised as a
dermatological curiosity which evolved into a multisystem disorder with
bone cysts, uveitis, and intrathoracic involvement. New dimensions were
uncovered by biochemistry and immunology, bringing it still nearer the
elusive enigma, namely the cause of sarcoidosis. Aetiology includes an
understanding of a genetic predisposition and environmental trigger
factors. What was left undone in the 20th century will become evident
in the 21st century with more sophisticated technology. Likewise,
conventional treatments of the past will be superseded by cytokines and
other magic bullets of the millennium.
Keywords: anergy; apoptosis; homoeostasis; cytokines
© 2001 by The Fellowship of Postgraduate Medicine
This article has been cited by other articles:
-
Fatahzadeh, M., Rinaggio, J.
(2006). Diagnosis of systemic sarcoidosis prompted by orofacial manifestations: A review of the literature. Journal of the American Dental Association
137: 54-60
[Abstract] [Full Text] -
Serio, R. N
(2003). Infliximab Treatment of Sarcoidosis. The Annals of Pharmacotherapy
37: 577-581
[Abstract] [Full Text]
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
